Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Peritoneal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Malignancies 1

Interventions

Paclitaxel 9Carboplatin 6Cisplatin 5Hyperthermic Intraperitoneal Chemotherapy 4Oxaliplatin 3Fluorouracil 3Cytoreduction Surgical Procedures 3Bevacizumab 3nintedanib 2Mitomycin 2Leucovorin 2Laparoscopy 2Gemcitabine 2Folfox protocol 2Docetaxel 2vandetanib 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1poly(I).poly(c12,U) 1pembrolizumab 1olaparib 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1farletuzumab 1enzastaurin 1catumaxomab 1birinapant 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Peritoneal Neoplasms × 1-dodecylpyridoxal × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡